Rimiducid [195514-63-7]
Referencia HY-16046-100mg
embalaje : 100mg
Marca : MedChemExpress
Descripciòn | |||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
IC50 & Target | |||||||||||||
In Vitro |
Rimiducid (AP1903) elicits potent and dose-dependent apoptotic death of these engineered cells in culture, with an EC50 of ≈0.1 nM[1]. Maximal killing occurred in the presence of 3 to 10 nM Rimiducid (AP1903), and the IC50 is approximately 0.2 nM. LV′VFas-transduced T lymphocytes expressing high levels of CD25 (top panel) are eliminated by with 66%±7.5% (n=10) efficiency. When cells are examined after CD25 expression returned to basal levels, 63%±4.7% (n=9) killing is observed after Rimiducid treatment[2]. MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. | ||||||||||||
Solvente y solubilidad |
In Vitro:
DMSO : ≥ 100 mg/mL (70.84 mM; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO) *"≥" means soluble, but saturation unknown. Preparing
Stock Solutions
View the Complete Stock Solution Preparation Table
* Please refer to the solubility information to select the appropriate solvent. The compound is unstable in solutions, freshly prepared is recommended. Select the appropriate dissolution method based on your experimental animal and administration route.
For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
|
||||||||||||
Pureza y Documentación |
Purity: 99.81% |
||||||||||||
Referencias |
|